NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March
NAARDEN, The Netherlands and MIAMI, Feb. 26, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in three upcoming investor conferences:
荷兰纳尔登和迈阿密，2024年2月26日（GLOBE NEWSWIRE）——新阿姆斯特丹制药公司（纳斯达克股票代码：NAMS 或 “新阿姆斯特丹” 或 “公司”），一家处于后期阶段的临床生物制药公司，为有心血管疾病风险且低密度脂蛋白胆固醇（“LDL-C”）升高、现有疗法不够有效或不够有效的患者开发口服非他汀类药物容忍度良好，今天宣布公司管理层将参加三次即将举行的投资者会议：
- TD Cowen 44th Annual Health Care Conference in Boston, MA on Monday, March 4, 2024. Michael Davidson, Chief Executive Officer, and Ian Somaiya, Chief Financial Officer, will present a corporate overview at 2:10 p.m. ET.
- Leerink Global Biopharma Conference in Miami, FL on Monday, March 11, 2024. Michael Davidson, M.D., Chief Executive Officer, will present a corporate overview at 4:00 p.m. ET.
-
Jefferies Biotech on the Bay Summit in Miami, FL on Tuesday, March 12, 2024. Company management will be available for 1x1 meetings throughout the day.
- TD Cowen第44届年度医疗保健会议将于2024年3月4日星期一在马萨诸塞州波士顿举行。首席执行官迈克尔·戴维森和首席财务官伊恩·索迈亚将在美国东部时间下午 2:10 介绍公司概况。
- Leerink全球生物制药会议将于2024年3月11日星期一在佛罗里达州迈阿密举行。首席执行官迈克尔·戴维森医学博士将在美国东部时间下午 4:00 介绍公司概况。
- 杰富瑞生物科技公司海湾峰会将于2024年3月12日星期二在佛罗里达州迈阿密举行。公司管理层将全天提供1x1会议。
Live webcasts of both the Cowen and Leerink presentations will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived replay will be available on the Company's website.
Cowen和Leerink演讲的网络直播将通过新阿姆斯特丹制药公司网站ir.newamsterdampharma.com的投资者关系栏目播出。网络直播结束后，公司网站上将提供存档重播。
About NewAmsterdam
关于新阿姆斯特丹
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as preferred LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
NewAmsterdam Pharma（纳斯达克股票代码：NAMS）是一家处于后期阶段的生物制药公司，其使命是改善目前批准的疗法不足或耐受性不佳的代谢性疾病患者的患者护理。我们力求满足对安全、耐受性好、便捷的降低密度脂蛋白疗法的巨大需求。在多项3期研究中，NewAmsterdam正在研究obicetrapib，一种口服、低剂量、每日一次的CETP抑制剂，单独使用或与依泽替米贝作为固定剂量组合的首选低密度脂蛋白C降低疗法，可用作他汀类药物治疗的辅助疗法，用于低密度脂蛋白C升高的心血管疾病的患者。
Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com
公司联系人
马修·菲利普
P：1-917-882-7512
matthew.philippe@newamsterdampharma.com
Media Contact
Spectrum Science on behalf of NewAmsterdam
Jen Gordon
P: 1-202-957-7795
jgordon@spectrumscience.com
媒体联系人
代表新阿姆斯特丹的频谱科学
詹·戈登
P：1-202-957-7795
jgordon@spectrumscience.com
Investor Contact
Stern Investor Relations on behalf of NewAmsterdam
Hannah Deresiewicz
P: 1-212-362-1200
hannah.deresiewicz@sternir.com
投资者联系人
Stern 投资者关系部代表 NewAmsterdam
汉娜·德雷西维奇
P: 1-212-362-1200
hannah.deresiewicz@sternir.com